Abionyx Pharma SA ABNX.PA
€2.20 €0.01 (0.30%) 1D
Last Updated: Jun 23, 12:00 AM·XPAR
Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
ABNX.PA Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: February 04, 2026
Report Source: 2025 2nd Quarter Report
Abionyx Pharma SA. Stock Analysis ABNX.PA
France Health Care Micro Cap Report: ABIONYX Pharma SA engages in the discovery and development of novel therapies for patients without existing or effective treatments. The company employs 49 full-time employees The company went IPO on 2015-03-30. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The firm is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.
Read More Abionyx Pharma SA (ABNX.PA) Chart
Key Statistics of Abionyx Pharma SA (ABNX.PA)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
€2.19Volume
132.83KP/E Ratio (TTM)
-52 Week Range
Market Cap
124.53MAvg. Volume
140.43KDividend Yield
-Financial Metrics & Statements of Abionyx Pharma SA (ABNX.PA)
FAQ's for Abionyx Pharma SA (ABNX.PA)
- According to Musaffa’s Shariah screening methodology, Abionyx Pharma SA (ABNX.PA) is currently classified as HALAL as of February 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Abionyx Pharma SA using these criteria to determine its compliance status.
- Muslim investors may consider investing in Abionyx Pharma SA if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Abionyx Pharma SA by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Abionyx Pharma SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Abionyx Pharma SA on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.